Home > Insider Trading > Filing (0001209191-20-062394)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1671858	Silverback Therapeutics Inc.	SBTX	Pharmaceutical Preparations (2834)	811489190

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1776412	Thilo Schroeder	C/O Silverback Therapeutics, Inc. 500 Fairview Avenue N, Suite 600 Seattle WA 98109		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-12-08	238,096	$21.00	238,096	No	4	P	Indirect	By Nextech VI Oncology SCSp
Common Stock	Acquisiton	2020-12-08	1,246,870	$0.00	1,484,966	No	4	C	Indirect	By Nextech VI Oncology SCSp
Common Stock	Acquisiton	2020-12-08	425,063	$0.00	1,910,029	No	4	C	Indirect	By Nextech VI Oncology SCSp

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Nextech VI Oncology SCSp
No	4	C	Indirect	By Nextech VI Oncology SCSp
No	4	C	Indirect	By Nextech VI Oncology SCSp

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2020-12-08	4,629,630	$0.00	1,246,870	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-12-08	1,578,259	$0.00	425,063	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

The shares were purchased in the Issuer's initial public offering.
Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.